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Objective: To provide a solid baseline reference for quality of life (QoL) in patients with no-option critical limb ischemia
(CLI). CLI is associated with surgery, endovascular interventions, hospitalization, and a poor prognosis. An increasing
number of clinical trials are, therefore, investigating new treatment strategies (eg, therapeutic neovascularization) in
patients with CLI. QoL serves as an important secondary endpoint in many of these trials, but solid reference QoL data
for patients with no-option CLI are lacking.
Methods: The Medical Outcomes Study Short Form 36 (SF-36) and the EuroQol-5D (EQ-5D) questionnaires were used
to obtain baseline QoL scores from 47 patients with no-option CLI participating in a therapeutic neovascularization trial.
To allow for easy comparability, a norm-based scoring (NBS) method was used to report the results of the SF-36. Scores
of patients with CLI were furthermore compared with scores of patients with milder forms of peripheral arterial disease
(PAD) and with patients with cardiovascular risk factors only. Determinants of QoL in patients with PADwere identified
using multiple linear regression methods.
Results: Patients with no-option CLI reported QoL scores below the general population mean on every health dimension
of the SF-36. Physical functioning, role physical functioning, and bodily pain were affected most intensively. These poor
physical QoL scores were further underlined when compared with other patients with milder forms of PAD or patients
with cardiovascular risk factors only. Patients with CLI scored poorly on the pain/discomfort and the usual activities
domain of the EQ-5D. Diabetes, female gender, body mass index, and the ankle-brachial index at rest were significant
determinants of the QoL in PAD on multivariate analysis.
Conclusion: The QoL data of patients with no-option CLI using NBS methods for the SF-36 provide a baseline reference
for ongoing clinical trials on new treatment strategies. Our data stress the need for new revascularization therapies in
patients with no-option CLI. (J Vasc Surg 2010;52:843-9.)Critical limb ischemia (CLI), defined as chronic rest
pain or tissue necrosis as a result of progressing peripheral
arterial disease (PAD), is an important health issue. Yearly,
CLI will develop in 500 to 1000 patients in a Western
population of 1 million people.1 It is associated with sur-
gery, hospitalization,2 and death, with 5-year survival rates
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doi:10.1016/j.jvs.2010.04.057of 50% or less being reported.3,4 Despite the rapid devel-
opment of interventional techniques, therapeutic options
for patients with CLI remain limited: approximately 40% of
patients with CLI are not eligible for surgical or endovas-
cular revascularization.5,6 No pharmacologic therapy has
proven to be effective,7 and ultimately, amputation is often
the only option left. New therapies are, therefore, urgently
needed. Angiogenic therapies by administration of growth
factors or bone marrow-derived stem or progenitor cells
seem to be promising treatment strategies and are currently
being evaluated in clinical trials in patients with no-option
CLI.8
Besides the improvement in clinical status, improving
the quality of life (QoL) of patients with CLI has become
an important treatment goal.1 QoL is, therefore, consid-
ered to be an important secondary endpoint in these trials.
This is particularly true because the assessment of vascular
growth as an endpoint for angiogenic studies remains dif-
ficult.9 To enable optimal evaluation of these trials and
comparisons between patient populations and treatment
strategies, standardized QoL assessments are important.
Between 1997 and 2008, 14 studies10-23 reported re-
duced QoL of patients with CLI using the Medical Out-
comes Study Short Form 36 (SF-36) Health Survey. This
QoL questionnaire is a widely accepted, reliable, and com-
monly used QoL assessment tool for various diseases24 and
843
JOURNAL OF VASCULAR SURGERY
October 2010844 Sprengers et alis considered the most appropriate generic QoL assessment
tool in patients with limb ischemia.10 Comparisons of these
studies of patients with CLI with QoL data obtained in
other disease states are hampered, however, by differences
in patient populations and inconsistent reporting of the
results.
To improve comparability with the same underlying
condition and with other diseases, a norm-based scoring
(NBS) method to evaluate SF-36 questions has been devel-
oped.24 The NBS method provides scores that are stan-
dardized in a way that mean general population scores are
the same (50) for every dimension, thereby serving as a
reference. Furthermore, the NBS method considers two
additional summary scores, the physical component score
(PCS) and the mental component score (MCS), which
allow independent assessment of the effect of a condition
on the physical and mental aspects of QoL.
To date, two studies have used the NBS method to
report the QoL in patients with CLI. One study reported
separate baseline NBS scores in 18 patients with CLI who
underwent angioplasty.18 The second study only reported
the summary scores of the NBS method in 452 patients
with CLI who were randomized to bypass surgery or bal-
loon angioplasty.17 Other studies have reported QoL
scores using conventional, untransformed SF-36 scores.
Equally sparse are studies reporting the QoL in patients
with PAD and CLI measured by the EuroQoL-5D (EQ-
5D), another widely acceptedQoL questionnaire. No stud-
ies addressing QoL in patients with CLI have focused on
patients with CLI without any options for revasculariza-
tion.
The purpose of this study was to present QoL scores in
patients with no-option CLI using two well-established
QoL questionnaires, the SF-36 and the EQ-5D. The SF-36
was scored using the NBSmethod, thereby introducing the
easily interpretable PCS and MCS. With the increasing
number of studies investigating new experimental therapies
in these patients with no-options, NBS scores in this pop-
ulation could serve as a useful baseline reference. In addi-
tion, we placed the QoL scores obtained in the patients
with no-option CLI in perspective with scores obtained in
patients with milder forms of PAD and cardiovascular risk
factors only. We also identified patient characteristics asso-
ciated with QoL in PAD.
METHODS
QoL data were analyzed from: (1) 47 patients with
CLI, with no surgical or endovascular options for revascu-
larization, who were included in the JUVENTAS trial; (2)
313 patients with milder PAD, defined as intermittent
claudication (grade II of the Fontaine classification), par-
ticipating in the SMART cohort; and (3) 1182 patients
withoutmanifest cardiovascular disease, but referred for the
treatment of cardiovascular risk factors, and for that reason
included in the SMART cohort. Both studies are con-
ducted in The Netherlands and patients originate from the
same geographic area.The JUVENTAS trial is an ongoing, randomized, pla-
cebo-controlled, double-blind clinical trial (registered on
clinicaltrials.gov under NCT00371371) that studies the
effects of repeated intra-arterial infusion of bone marrow
mononuclear cells in patients with unreconstructable CLI.
Patients with a Fontaine classification of IIb, III, or IV, and
an ankle-brachial index (ABI) of less than 0.6 or unreliable
(noncompressible or not in proportion to the Fontaine
classification), and who were not suitable for conventional
revascularization were eligible for participation in this trial.
Exclusion criteria were neoplasm or malignancy in the past
10 years, concomitant disease with life expectancy of less
than 1 year, inability to obtain sufficient bone marrow
aspirate, known infection with human immunodeficiency
virus or hepatitis B or C virus, and inability to complete
follow-up. The present study used baseline QoL data ob-
tained at inclusion of patients with CLI (Fontaine III or IV)
included in this trial in the period between September 2006
and July 2009.
The SMART study is an ongoing, prospective, single-
center, cohort study of patients with clinically manifest
vascular disease or cardiovascular risk factors only. The
rationale and design of the SMART study have been de-
scribed in detail elsewhere.25 The SMART study popula-
tion comprises patients who are newly referred because of
manifest arterial disease or cardiovascular risk factors. All
patients undergo a detailed examination at baseline, are
followed-up with regard to their cardiovascular risk, and
complete QoL questionnaires at inclusion. Our study used
baseline data from patients included in the SMART study in
the period between September 1996 and March 2007.
Questionnaires. The SF-36 consists of 35 items cov-
ering eight health dimensions and an additional item that
assesses the change in general health status over time. The
scores on each health dimension are summed and trans-
formed on a scale from 0 (worst health) to 100 (best
health).24 The SF-36 questions were additionally scored
using the NBS method.24 NBS scores for each of the eight
health dimensions were obtained by first standardizing the
score on each health dimension by subtraction of the
population mean of the score for that specific dimension
and dividing the difference by the population’s SD (Z-
score). A norm-based transformation was conducted by
multiplying the product of the former calculation by 10 and
adding 50 to this product.
Next, the PCS and MCS scores were calculated. Both
scores are obtained by adding the Z-scores of the eight health
dimensions, eachmultiplied by a specific weight factor.24 This
specific weight factor for each dimension is based on the
impact of the dimension on either the PCS or MCS and is
corrected for interactions between individual dimensions. The
PCS and MCS thus take into account the correlations be-
tween the eight SF-36 dimensions and, therefore, reflect the
effect of a condition on either the physical or mental compo-
nent of health. To calculate the NBS score, the 1998 United
States population normswere used, which have been used in a
wide variety of conditions.24
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and reliable in a wide variety of diseases.10,26 The EQ-5D is
composed of five items covering five domains of QoL,
comprising mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. Problem severity on each
of the five domains is rated as having “no problems” (level
1), “some problems” (level 2), or “extreme problems”
(level 3). Combining the level of health problems on each
domain results into 243 (35) possible health states (exclud-
ing death). Each health state was converted to a scale ranging
from1 to1, using the Preference-Based EuroQoL Tariff
reported by Dolan.27
We used a visual analogue scale (VAS) to measure the
experienced pain across a continuum of values. The VAS
was anchored between 0 (no pain at all) and 10 (unbearable
Table I. Patient characteristics
JUVENTA
Male gender 33 (
Age (mean [SD]) 65.2 (
Smoking status:
Never smoked 4 (
Current smoker 13 (
Former smoker 30 (
Diabetes 15 (
History of hypertension 26 (
Systolic BP (mm Hg, mean [SD]) 143.0 (
History of hypercholesterolemia 33 (
Lipids (mmol/L, mean [SD]):
Total cholesterol 4.5 (
HDL-cholesterol 1.3 (
LDL-cholesterolc 2.5 (
Triglycerides 1.7 (
Body mass index (kg/m2, mean [SD]) 25.2 (
Hyperhomocysteinemia 14 (
Homocysteine (mol/L, mean [SD]) 16.1 (
Creatinine (mol/L, mean [SD]) 103.0 (
Medical history:
Previous revascularization 39 (
Myocardial infarction or angina 19 (
CABG 10 (
Stroke 5 (
Transient ischemic attacks 5 (
End-stage renal disease 1 (
Fontaine classification:
Stage IIA/B 0 (
Stage III 22 (
Stage IV 25 (
ABI at rest (mean [SD]) 0.47 (
Use of analgesics:
None 14 (
Paracetamol 6 (
Nonsteroidal anti-inflammatory drugs 2 (
Opioids 24 (
Pain-free walking distance (m, mean [SD]) 55.6 (
Maximum walking distance (m, mean [SD]) 146.5 (
ABI, Ankle-brachial index; BP, blood pressure; CABG, coronary artery byp
factors; VAS, visual analog scale.
Data are number (%) in case of categorical variables and mean (SD) in case
aSignificant difference with JUVENTAS (P  .05).
bSignificant difference between PAD and RF (P  .05).
cLDL-cholesterol calculated using Friedewald calculation.
dData not available for second manifestations of arterial disease (SMART)-ppain).Data analysis. Data were analyzed using SPSS 15.0.1
software (SPSS Inc, Chicago, Ill). For the SF-36, missing
items (1% of the total items) were imputed if at least 50% of
the items had been completed for each health dimension.
The missing items were replaced by the mathematic mean
of the residual items of that specific health dimension.24
One-way analysis of variance was used in conjunction with
a Bonferroni post hoc analysis to test for differences be-
tween continuous baseline characteristics, QoL dimen-
sions, and summary scores for patients with CLI, PAD, and
cardiovascular risk factor. The Fisher exact test was used for
categoric differences. Correspondence of different dimen-
sions of the SF-36 and EQ-5D, and of QoL dimensions
considering pain and the VAS pain score, were tested using
bivariate correlation and reported as the Pearson correla-
47) PAD (n  313) Risk factors (n  1182)
206 (66%) 632 (54%)b
58.5 (10.7)a 47.6 (13.3)a,b
29 (9%) 438 (37%)a,b
127 (41%)a 274 (23%)b
157 (50%)a 468 (40%)a,b
77 (25%) 338 (29%)
184 (59%) 737 (62%)
146.8 (21.3) 145.9 (22.3)
189 (60%) 782 (68%)
5.3 (1.2)a 5.8 (1.6)a,b
1.3 (0.4) 1.4 (0.5)b
3.2 (1.0)a 3.5 (1.4)a,b
1.9 (1.3) 2.2 (3.0)
26.5 (4.0) 27.2 (5.3)a
36 (11.5%)a 93 (8%)a
13.0 (4.8) 12.2 (11.0)a
94.6 (63.0) 84.2 (20.5)a,b
26 (8.3%)a 0 (0%)a,b
46 (14.7%)a 0 (0%)a,b
d d
14 (4.5%) 0 (0%)a,b
d d
d d
313 (100%)a 0 (0%)a
0 (0%)a 0 (0%)a
0 (0%)a 0 (0%)a
0.75 (0.22)a 1.14 (0.12)a,b
d d
)
)
)
Treadmill test not performed
Treadmill test not performed
aft; HDL, high-density lipoprotein; LDL, low-density lipoprotein; RF, risk
tinuous variables.
s.S (n 
70%)
11.4)
8%)
28%)
64%)
33%)
59%)
22.1)
75%)
1.3)
0.5)
1.0)
1.1)
4.0)
30%)
6.1)
42.9)
83%)
40%)
21%)
11%)
11%)
2%)
0%)
47%)
53%)
0.33)
30.4%
13.0%
4.3%)
52.2%
52.2)
73.0)
ass gr
of contion coefficient.
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PAD, CLI, and PAD were analyzed as one patient group.
We also performed stratified analyses for age and gender.
Therefore, patients were age stratified into two groups
(above and below the median) and additionally stratified by
gender. Patient characteristics potentially associated with
QoL dimensions were selected based on clinical judgment
and previous reports.28,29 Relationships between these fac-
tors and the PCS and MCS were tested for normality,
linearity, and homoscedasticity before multivariate linear
regression was conducted. Factors with a value of P  .10
on univariate analysis were selected for the multivariate
linear regression analysis. Statistical significance was set at P
 .05. Mean data are presented with the 95% confidence
interval (CI).
RESULTS
Patient demographics. The CLI group (JUVENTAS
participants) had a mean age of 65.2 11.4 years and 70%
were men. By Fontaine grade, 47% were at grade III and
the rest were at grade IV. Cardiovascular risk factors were
abundantly present: 92% smoked or were currently smok-
ing, 59% had a history of hypertension, 75% had hypercho-
lesterolemia, and diabetes was present in 33%. SF-36 data
were available for 46 of the 47 patients and EQ-5D data for
all patients.
Table I reports the baseline characteristics of all pa-
tients. JUVENTAS patients were significantly older, under-
went more revascularizations, had sustained more myocar-
dial infarction, and had a lower resting ABI. All patients
with milder PAD (SMART patients) were at Fontaine
grade II, whereas none of the SMART patients with risk
factors only were at Fontaine grade II, III, or IV.
Patients with CLI have poor physical QoL. Patients
with CLI demonstrated low scores for every dimension of
the SF-36 (Fig 1 and Table II). Mean NBS scores were well
below 50 (general population mean). Worst scores were
obtained for the physical health domains, including physi-
cal functioning, role physical functioning, and bodily pain.
This poor physical health is also reflected by the low mean
PCS score of 30.8 (95% CI, 28.8-32.9). The physical
functioning score of patients with CLI was two SDs below
the general population mean, indicating very severe prob-
lems. No differences for SF-36 NBS scores were observed
between patients with CLI at Fontaine grade III or IV (data
not shown).
On the EQ-5D, patients with CLI scored worst on the
subscales pain/discomfort (0.0%, 63.8%, and 36.2% scor-
ing level 1, 2, and 3, respectively) and usual activities
(10.6%, 61.7%, and 27.7% scoring level 1, 2, and 3, respec-
tively). The subscales bodily pain and mental health of the
SF-36 and pain/discomfort and anxiety/depression of the
EQ-5D were highly corresponding (R2  .549 and R2 
.729, respectively; P  .05). The subscales bodily pain of
the SF-36 and pain/discomfort of the EQ-5D both corre-
lated with the VAS pain score (mean, 5.1; 95% CI, 4.4-5.8)
at R2  .454 and R2  .398, respectively (P  .05).QoL in patients with CLI is worse than in PAD and
risk factors. Patients with no-option CLI showed signifi-
cantly lower QoL scores than patients with PAD, especially
with regard to the physical domains (Fig 2, Table III). This
was confirmed by the significantly lower PCS (mean differ-
ence, 6.8; 95% CI, 9.9 to 3.7) for patients with CLI.
The PCS also showed a decreasing trend with increasing
disease severity: the means for PCS were 30.8 (95% CI,
28.8-32.9), 37.6 (95% CI, 36.5-38.8), and 48.4 (95% CI,
47.8-49.0) in patients with CLI, PAD, and cardiovascular
risk factors, respectively. The MCS for these three groups
were 45.9 (95% CI, 41.4-50.4), 51.4 (95% CI, 50.2-52.7),
and 47.8 (95% CI, 47.1-48.4), respectively.
QoL in CLI and PAD correlates with nonmodifi-
able risk factors. Analyzing the 47 patients with CLI
and the 313 patients with SMART-PAD together re-
sulted in 360 patients with any degree of PAD. When
stratified by age and gender, no significant differences
were found for the PCS. The MCS was significantly
lower for the older females. Univariate analysis showed
that older age, female gender, previous revascularization,
history of myocardial infarction, history of stroke, higher
BMI, previous or current smoking, hyperhomocysteine-
mia, hypertension, hypercholesterolemia, diabetes,
higher serum creatinine level, lower ABI at rest, and
higher PAD staging by Fontaine classification were asso-
ciated with lower PCS scores. On multivariate linear
regression analysis, a history of diabetes, female gender,
a higher BMI, and a lower ABI remained as significant
determinants of a reduced PCS score (adjusted model
R2  .137). No relation was found between patient
Fig 1. Mean values of quality-of-life indices and 95% confidence
intervals (error bars) for 46 patients with critical limb ischemia
(CLI) using the norm-based scoring method. The general popu-
lation norm is 50, as indicated, for every dimension. BP, Bodily
pain; GH, general health; MCS, mental component summary
score; MH, mental health; PCS, physical component summary
score; PF, Physical functioning; RE, role-emotional; RP, role-
physical; SF, social functioning; VT, vitality.characteristics and the MCS score.
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Using the NBS method, we show that patients with
no-option CLI have worse outcomes in essentially every
SF-36 domain of QoL compared with patients with milder
forms of PAD (Fontaine II) and cardiovascular risk factors
only. Multivariate linear regression showed that the QoL in
patients with PAD mainly depends on gender and other
factors such as diabetes, BMI, and resting ABI that cannot
Table II. Mean SF-36 (n  46) and EQ-5D (n  47) val
SF-36 health dimension
Scoring method
SF-36 NBS SF-36 C
Physical functioning 28.0 (25.2-30.9) 30.6 (23.8-3
Role physical 34.4 (31.3-37.5) 22.8 (11.9-3
Bodily pain 32.9 (30.5-35.4) 30.4 (24.7-3
General health 39.7 (36.7-42.7) 48.1 (41.7-5
Vitality 44.8 (41.4-48.2) 46.0 (38.8-5
Social functioning 36.9 (32.7-41.2) 53.5 (43.6-6
Role emotional 39.5 (35.2-43.7) 49.8 (36.3-6
Mental health 42.6 (38.4-46.8) 62.3 (54.9-6
PCS 30.8 (28.8-32.9) a
MCS 45.9 (41.4-50.4) a
CLI, Critical limb ischemia; CS, conventional scoring; EQ, Euro-Qol;MCS,
Score; SF-36, Short Form 36.
Values are mean (95% confidence interval).
aPCS and MCS only calculable with NBS.
bTariff score by Dolan Conventional scoring of SF-36 are untransformed
scoring. Conventional scores range from 0 to 100.
Fig 2. Mean values of quality-of-life indices and 95% confidence
intervals (error bars) for 46 patients with critical limb ischemia
(CLI) compared with patients with peripheral arterial disease
(PAD) or cardiovascular risk factors (RF) only. The general popu-
lation norm is 50, as indicated, for every dimension. BP, bodily
pain; GH, general health; MH, mental health; MCS, mental com-
ponent summary score; PF, Physical functioning; PCS, physical
component summary score; RP, role-physical; RE, role-emo-
tional; SF, social functioning; SMART, second manifestations of
arterial disease (SMART); VT, vitality. * Significant difference
JUVENTAS vs PAD and risk factors (P  .05). Significant differ-
ence PAD vs RF (P  .05).be easily modified by therapeutic interventions.Poor QoL of patients with CLI has been reported in
several publications in the past decade using the SF-
36.10-23 We used the NBS method for the SF-36. The
norm-based transformation of the scores to general popu-
lation means allows comparison of the physical and mental
components of the health of patients with similar and other
underlying conditions. The NBS method has been used in
a wide variety of physical andmental conditions,24,30,31 but
its use in patients with PAD or CLI populations has been
limited. To our knowledge, our study provides the first
NBS data on QoL in patients with no-option CLI, which
thereby may provide a baseline reference for this patient
group. Using this standardized methodology may improve
evaluation of the many ongoing clinical studies on angio-
genic therapies by enabling comparisons between patient
populations. Furthermore, our data show that the PCS in
our population of patients with no-option CLI (score,
or patients with CLI
EQ-5D dimension
Frequency of scores (%)
1 2 3
Mobility 0.0% 95.7% 4.3%
Self-care 68.2% 27.3% 4.5%
Usual activities 10.6% 61.7% 27.7%
Pain/discomfort 0.0% 63.8% 36.2%
Anxiety/depression 50.0% 34.8% 15.2%
Overall score 0.34 (0.24-0.44)b
al Component Score;NBS, norm-based scoring; PCS, Physical Component
and provided to facilitate comparison with studies not using norm-based
Table III. SF-36 scores PAD vs CLI
SF-36 Health dimension
SF-36 NBS
PAD (n  313) CLI (n  46)
Physical functioning 36.4 (35.3-37.4) 28.0 (25.2-30.9)a
Role physical 41.4 (40.1-42.8) 34.4 (31.3-37.5)a
Bodily pain 43.1 (41.9-44.3) 32.9 (30.5-35.4)a
General health 41.5 (40.5-42.5) 39.7 (36.7-42.7)
Vitality 48.9 (47.8-50.0) 44.8 (41.4-48.2)a
Social functioning 43.7 (42.4-45.0) 36.9 (32.7-41.2)a
Role emotional 48.4 (47.1-49.7) 39.5 (35.2-43.7)a
Mental health 48.1 (46.9-49.2) 42.6 (38.4-46.8)a
PCS 37.6 (36.5-38.8) 30.8 (28.8-32.9)a
MCS 51.4 (50.2-52.7) 45.9 (41.4-50.4)a
CLI, Critical limb ischemia; MCS, Mental Component Score; NBS, Norm-
based scoring; PAD, peripheral arterial disease; PCS, Physical Component
Score.
Values are mean (95% CI).
aSignificant difference between Fontaine II and III/IV.ues f
S
7.5)
3.8)
6.1)
4.6)
3.1)
3.3)
3.2)
9.6)
Ment
scores30.8) is significantly worse than scores previously obtained
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(score, 39.4), and chronic kidney disease (score, 36.8),24
underlining the need for improved treatment of these pa-
tients.
We identified gender, diabetes, BMI, and resting ABI
as factors associated with QoL (ie, PCS) in PAD, of which
gender cannot be modified and the others are not easily
modified. Although BMImay be influenced to some extent
by therapeutic intervention, long-term weight reduction
seems hard to achieve,32 and functional limitations in pa-
tients with CLI make this particularly difficult in these
patients. The association between QoL and resting ABI
again underscores the importance of revascularization and
thus the need for development of new treatment strategies
in these patients with no-option CLI.
Despite analgesia use in 70% of the patients with CLI,
they had a particularly low PCS score, with bodily pain as
one of the physical QoL factors that is strikingly poor
(mean, 32.9; 95% CI, 30.5-35.4). This is consistent with
the relatively high mean VAS pain score of 5.1 (95% CI,
4.4-5.8) in our patients and in line with reports indicating
that ischemic pain is hard to suppress.33,34 It shows that
pain management is essential in improving QoL, which
may require amultidisciplinary approach in patients who do
not have the option of revascularization.
In conclusion, this study provides QoL data in patients
with no-option CLI using the NBS method for scoring the
SF-36, hence providing a baseline reference for the increas-
ing number of clinical trials in this patient group. The
results of this study show that the physical component of
health is exceptionally poor in these patients, with pain as
an important determinant. Our data stress the need for
development of management strategies to avoid patients to
reach a no-option status. Moreover, it underlines the need
for new revascularizing treatment options in patients with
CLI who currently have no options for surgical or endovas-
cular revascularization.
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